Global Rosai-Dorfman Disease Market - 2023-2030

Overview

Global Rosai-Dorfman Disease Market reached US$ 405.0 million in 2022 and is expected to reach US$ 667.5 million by 2030, growing with a CAGR of 6.6% during the forecast period 2023-2030.

Rosai-Dorfman disease (RDD) is a rare, benign condition that involves an overgrowth of white blood cells called histiocytes. It usually causes swollen lymph glands in the neck, but overgrowths can also affect to skin and other organs. Symptoms, treatment options and likely outcomes vary from person to person.

Most people with Rosai-Dorfman disease are children, teenagers, and young adults. The average age of Procedure Type for RDD is around 20, but incidences of RDD involving adults in their 70s have been documented. People of African origin who are born male most typically get RDD that affects the lymph nodes. People of Asian heritage who are assigned to the female gender at birth are most commonly diagnosed with cutaneous RDD. Most CRDD sufferers are in their 20s, 30s, and 40s.

RDD may have several reasons because each person is affected by it differently. For instance, current research indicates that CRDD is likely to have distinct aetiology from traditional RDD. Rosai-Dorfman disease is not the only extranodal RDD type that occasionally exhibit gene alterations, according to current research. A cell's growth might become uncontrolled due to gene mutations.

Dynamics

The Rise of FDA Approvals

Due to its unique histology and clinical characteristics, RDD is an interesting disease that has sparked the interest of researchers and medical professionals. Understanding RDD can help researchers better understand how the immune and lymphatic systems function in both health and sickness. The number of RDD clinical trials may have increased. These trials are crucial for evaluating novel therapies, and if any of them yield positive findings, the FDA might approve specific drugs or therapies.

For instance, January 30, 2023, For the treatment of adult patients with histiocytic neoplasms like Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis, the FDA has approved cobimetinib (Cotellic). The regulatory choice was supported by information gathered as a result of a partnership between Genentech and Memorial Sloan Kettering (MSK) Cancer Centre.

According to data from the single-center, one-arm trial, cobimetinib produced an objective response rate (ORR) of 76.9% by PET and 46.2% by RECIST criteria in 26 recruited patients at a median follow-up of 11.4 months. The diligent work of several MSK researchers over the course of several years of research culminated in the approval of cobimetinib. As a result of the research and clinical trials carried out at MSK, there have been enormous advancements in the field of uncommon malignancies. Thus above factors helps to boost the market growth.

Raising Awareness of Rosai-Dorfman Disease

Rosai-Dorfman Disease treatment options are being developed as a result of rising Rosai-Dorfman Disease awareness. RDD is a rare disease that can be difficult to detect and treat, and both healthcare professionals and the general population sometimes have little understanding of the condition. However, there is rising understanding of the significance of early diagnosis and proper treatment as more information regarding RDD becomes accessible.

Through patient support networks and advocacy groups, RDD is becoming more widely known. These groups look for to increase understanding of RDD and offer information and support to patients and their families. These groups aid in raising public and professional awareness of RDD by sharing knowledge and personal experiences.

An additional significant method for raising awareness of RDD is through medical conferences and educational initiatives. These events give scholars, doctors, and executives from businesses the chance to exchange the most recent research findings and treatments. These occasions assist to raise awareness and understanding of RDD, which enhances the standard of care for patients with RDD. Thus above factors helps to accelerate the market growth.

Limited Treatment Options for the Rosai-Dorfman Disease

Compared to more widespread disorders, RDD is a rare disease, thus there are fewer patients to study and fewer resources available for research. It is difficult to conduct extensive clinical studies and create tailored treatments because of the low prevalence. RDD's precise cause and underlying mechanisms are not completely understood. The development of focused medicines is hampered by this lack of knowledge.

Histiocytes, an immunological cell type, are produced excessively in RDD, however it is unclear what causes this excessive production. RDD is a heterogeneous condition, which means that it can manifest differently in various people. While some people have mild or self-limiting illnesses, others might have more serious signs or problems. Thus, the market's expansion will be hindered by the limited treatment options for the RDD.

Segment Analysis

The global rosai-dorfman disease market is segmented based on type, age group, procedure type, end user and region.

Chemotherapy Play a Critical Part in the Treatment of RDD

Chemotherapy is not typically the first-line treatment for rosai-dorfman disease. RDD is a rare disorder characterized by the overproduction and accumulation of histiocytes (a type of immune cell) in lymph nodes and other tissues. The choice of treatment for RDD depends on the severity of the disease, its location, and the symptoms it causes.

The primary treatment for RDD usually involves a watch-and-wait approach, especially for cases where the disease is mild and not causing significant symptoms or organ dysfunction. In such cases, spontaneous regression or no progression of the disease is common, and treatment may not be necessary. However, if RDD is causing severe symptoms, such as organ dysfunction, pain, or compression of vital structures, treatment may be required.

Additionally, chemotherapy may be considered in cases of RDD with widespread or systemic involvement, particularly when other treatments have failed or when rapid progression is observed. Various chemotherapy regimens have been used, including corticosteroids, vinca alkaloids, and immune-modulating agents.

Geographical Penetration

Rising Clinical Trails and Product Launches in the North American Region

North America dominates the global rosai-dorfman disease market primarily due to its large population, excellent medical infrastructure, and high-income levels. The global rosai-dorfman disease is based on a number of micro- and macroeconomic variables. The prevalence of diseases associated with blood like cancer and viral infections contributes to the market's expansion.

Increased need for faster diagnosis led companies in the region to concentrate on more sophisticated methods. It is expected that an increase in clinical trials that have not yet received approval will accelerate market expansion. It is anticipated that the drug manufacturers will benefit as more individuals sign up for clinical trials as a result of increased consumer knowledge of blood-related diseases among consumers brought on by doctors, patients, advocacy groups, and researchers.

Throughout the projected period, the Asia Pacific is expected to witness fastest growth. Government programmes aimed at helping people with orphan diseases are to blame for the region's expansion.

COVID-19 Impact Analysis

Healthcare systems in numerous regions noticed serious difficulties during the COVID-19 epidemic, including resource shortages and disruptions in regular medical treatment. Access to healthcare services, including monitoring and treatment of RDD patients' conditions, may have been impacted by this. Clinical trials and research have been hampered by the epidemic in many different medical specialties. The pandemic may have slowed down or damaged RDD research, which could have slowed down the understanding and treatment of the condition.

By Type

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

By Age Group

• Children
• Adults

By Procedure Type

• Diagnosis
  • Imaging procedures
    • MRI
    • CT scan
    • Nuclear medicine

• Blood tests

• Biopsy
  • Treatment
    • Surgery
    • Radiation therapy
    • Chemotherapy
    • Corticosteroids
    • Immunotherapy

By End User

• Hospitals
• Diagnostic centers
• Cancer centers

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On November 28, 2022, at a city private hospital, a patient with Rosai-Dorfman disease (RDD), a rare immunological condition that had compromised his heart, was effectively treated. Only eight cases of the illness that affects the eyes and the heart have been reported so far in the entire world.

Competitive Landscape

The major global players in the market include: Koninklijke Philips N.V., GE HealthCare, Canon Inc, Siemens Healthineers, SternMed GmbH, Jubilant Cadista Pharmaceuticals Inc, LGM Pharma, Henan Lihua Pharmaceutical Co., Ltd, Niksan Pharmaceutical, Sandoz Canada Inc and among others.

Why Purchase the Report?

• To visualize the global rosai-dorfman disease market segmentation based on type, age group, procedure type, end user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of rosai-dorfman disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Rosai-Dorfman Disease market report would provide approximately 61tables, 58figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies